Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epinephrine spray for prevention of post-ERCP pancreatitis
IRCT20201128049521N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of epinephrine in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Amylase level within 24 hours after ERCP and Lipase level within 24 hours after ERCP. Started Sep 2018; status: completed.
02
Drugs
epinephrine
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on IRCT20201128049521N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201128049521N1.